Publication Archive
Altamura – Conferito il titolo di “Leonessa di Puglia” a Patrick Girondi e Angelantonio Tragni. Cittadinanza onoraria al dott. Tommaso Moretti
June 13, 2026
In un clima di grande compostezza e partecipazione, venerdì 12 giugno 2026 la sala consiliare del Comune di Altamura ha ospitato la cerimonia di conferimento delle prestigiose onorificenze cittadine. Nel corso dell’evento sono stati assegnati il titolo di “Leonessa di Puglia” a Patrick Girondi e all’Ispettore Superiore della Polizia Locale Angelantonio Tragni, mentre al dott. Tommaso Moretti è stata conferita la cittadinanza onoraria della città di Altamura.
San Rocco Therapeutics Unveils Promising “MiNiRoLu” Gene Therapy Data at ASGCT
May 19, 2026
According to the company, the SRT8 “MiNiRoLu” vector demonstrated approximately 30% higher functional titer, 35% greater transduction efficiency, and roughly 40% higher β-globin expression compared to an earlier lentiviral platform known as TNS9.3.55. Investigators also reported a favorable genomic integration profile, an important safety consideration in lentiviral gene therapy development.
San Rocco Therapeutics announces their Next-Generation Gene Therapy for Hemoglobin Disorders
April 30, 2026
San Rocco Therapeutics (SRT) today announced two abstracts at the upcoming 2026 ASGCT Annual Meeting highlighting its gene therapy platform, MiNiRoLu (SRT8-T87Q), and a companion diagnostic for quantifying therapeutic gene expression. These advances address key limitations of current gene therapies for hemoglobin disorders, including high cost, manufacturing complexity, and challenging drug monitoring.
Professors Frank Park and Andrew Wilber Win the Prestigious 2025 Orphan Dream Award
February 25, 2026
Biomedical researchers Frank Park, Ph.D., an Associate Professor at the University of Tennessee Health Science Center (UTHSC), and Andrew Wilber, Ph.D., an Associate Professor at Southern Illinois University School of Medicine, have been awarded the ninth annual Orphan Dream Award for their groundbreaking work advancing MiNiRoLu, a next-generation gene therapy designed to treat Sickle Cell Disease and Thalassemia.
The Gene Therapy No One Is Talking About: San Rocco and the Cost of Silence in Sickle Cell Care
February 5, 2026
As the biotech press dissects operational delays facing Vertex Pharmaceuticals’ CRISPR-based therapy for sickle cell disease, one gene therapy program has remained conspicuously absent from mainstream coverage: San Rocco Therapeutics (formerly Errant Gene Therapy). This is a venture that TrialSite News has showcased since our full first year in 2019. That silence is notable—not because San Rocco is promotional, well-capitalized, or media-savvy, but precisely because it is none of those things.
From Bench to Bedside: Why the University of Tennessee–San Rocco Story Reframes the Gene Therapy Debate
January 14, 2026
TrialSite News has spent years documenting a quieter but consequential counter-narrative in gene therapy—one that shifts attention away from prestige approvals and toward who actually gets cured. At the center of that story is San Rocco Therapeutics, whose work with academic partners reflects an access-first philosophy rarely foregrounded in mainstream coverage.
Researcher Pioneers Faster, Cheaper Gene Therapy for Hemoglobin Disorders
January 9, 2026
For millions living with hemoglobin deficiencies such as sickle cell disease or beta thalassemia, every day is a battle against pain, costly treatments, and uncertainty. Dr. Frank Park is racing to help.
The Cure Is Real. The Bottleneck Isn’t Scientific. So Why Is San Rocco Missing From the Story?
December 31, 2025
Two years after the U.S. Food and Drug Administration (FDA) first approvals of gene therapies for sickle cell disease, the central question is no longer whether cures are possible. It is who actually gets cured—and at what cost. That paradox sits at the center of a recent Politico investigation: spectacular science constrained by multimillion-dollar price tags, scarce treatment infrastructure, and payer bureaucracy so burdensome that many patients—especially Medicaid patients and those outside major metros—remain stuck in line.
The Great Cell and Gene Therapy Reckoning: From Revolutionary Promise to Industry Crossroads
October 24, 2025
Just days ago, on October 21, Belgian biotech Galapagos became the latest major casualty in what can only be described as a crisis of confidence sweeping through the cell and gene therapy CCGTF sector. The company announcedHiI it would shutter its entire cell therapy division: cutting 365 jobs and closing facilities across the Netherlands, Switzerland, the United States, and China.
Fetal vs Adult Hemoglobin: The Divide at the Heart of Gene Therapy
October 4, 2025
For decades, sickle cell disease has stood as one of medicine’s starkest unmet needs: one genetic mutation leading to painful crises, shortened lives, and limited treatment options. Patients with transfusion-dependent thalassemia faced a similar fate, relying on lifelong transfusions and iron chelation with no durable cure in sight. Bone marrow transplant was a hope for a few with compatible donors, but for the rest, treatment consisted of symptom management.
San Rocco Therapeutics annuncia una rinascita simbolica in vista dei test clinici per l'anemia falciforme e talassemia
July 17, 2025
San Rocco Therapeutics (SRT) è orgogliosa di annunciare la rinascita della sede europea dell’azienda in Italia, ad Altamura, con il restyling artistico delle tre grandi statue presso gli uffici in vista delle sperimentazioni cliniche sull’anemia falciforme e la beta-talassemia.
San Rocco Therapeutics Announces Symbolic Rebirth Ahead of Clinical Trials for Sickle Cell Disease and Thalassemia
July 16, 2025
San Rocco Therapeutics (SRT) proudly announces the revitalization of the European company headquarters in Altamura, Italy and the artistic makeover of the three huge statues which surround the edifice, in preparation for Sickle Cell Disease and Thalassemia clinical trials.
Gene Therapy Pipeline for SCD and Thalassemia—Cost and Access Become Key Under Kennedy HHS
June 28, 2025
An unfolding pipeline of gene therapies promises functional cures by fixing or replacing the defective gene. In late 2023, the FDA approved the first two gene therapies for SCD, marking a historic breakthrough.
Can a Father’s Quest to Save his Son from a Crippling Disease Lead to Affordable Gene Therapy for All?
March 26, 2025
Patrick Girondi, a former trader turned health advocate, is urging Health and Human Services Secretary Robert F. Kennedy Jr. and U.S. Attorney General Pam Bondi to investigate what he calls a decades-long conspiracy that blocked affordable gene therapy, costing lives and money.
Patrick Girondi, Renowned Artist, Lends Support to Robert F. Kennedy Jr. in Goal of Accessible Healthcare for Americans
May 19, 2023
Patrick Girondi, CEO of San Rocco Therapeutics (SRT) met Wednesday, May 17, 2023 with Robert F. Kennedy Jr. who is running for the Democratic Party nomination for U.S.A. President.
RICO Lawsuit against pharma bosses
May 5, 2023
San Rocco Therapeutics file an action for violations of federal RICO (Federal Racketering and Corrupt Organizations Act), fraudulent inducement and unfair…
41esima edizione del Premio Sicilia, un grande successo con ospiti e premi internazionali
May 3, 2023
Il Cineteatro Santa Caterina, a Rosolini, ha ospitato la 41esima edizione del Premio Sicilia…
A Father's Fight For a Gene Therapy
October 16, 2015
Patrick Girondi issuing Memorial Sloan Kettering to regain the license to a gene therapy for a blood disease.
Pat, il filantropo che non ti aspetti
February 18, 2010
Patrizio Girondi ha presentato alla redazione di Vita la sua fondazione Orphandream che sostiene la ricerca scientifica per la lotta alle malattie rare…
Pat, un pugliese a Chicago angelo dei talassemici
February 8, 2009
Guardate la foto qui accanto di Pat, mentre fa campagna elettorale a Bari per Barack Obama presidente, qualche mese fa: tipo bizzarro, vero?…
LA NUOVA AMERICA/A Chicago la festa dei pugliesi per Obama
November 6, 2008
BARI – Anche al «W Bari» di Chicago, un bar dove si riunisce la folta comunità di Carbonara trasferitasi nell’Illinois, è stata festa grande, ieri l’altro…
Un «cuore» barese contro la talassemia
September 7, 2006
Sul web l’impresa dell’italo-americano Pat Girondi…
Modern-day Robin Hood
June 1, 2007
The foundation soon morphed into the Robin Hood Orphan Disease Association, a nonprofit that creates awareness and organizes volunteers and donors to help fight rare diseases.
Biotech entrepreneur Girondi seeks orphan disease, son's cure
August 28, 2006
Patrick Girondi is a Chicago biotech entrepreneur who wants to save his son’s life…
Nato in America, curato ad Altamara
September 23, 2006
Il furto di due ruote d’auto e ll erick ehe si ferma a mezzaria…
One Man's Story: Born in America, Highly Considered in Altamura
September 1, 2006
Pat has a son with Thalassemia, a disease that is little known in Pat’s home Chicago written by Onofrio Pepe…
Mondo Scienza: Progressi verso il trattamento genetico della Beta-Thalassemia
December 1, 2004
Il trattamento genetico della b-talassemia ha lo scopo di eliminare il bisogno della…
When Vision Becomes Reality
November 1, 2004
Renaissance: Journal of the University of Notre Dame College of Science – Fall 2004, Volume 1, Number 2
Sto bene perché faccio del bene
January 1, 2002
Finalmente i lettori di Leonessa hanno la possibilitia della conoscenza ravvicinata di un affezionato ospite della nostra citta, di un amante di Altamura…
A father's love: Girondi combats deadly disorder
February 4, 1994
Casting about for an alternative cure, Girondi unearthed an experimental drug known as arginine butyrate, which “activates” a gene that ceases to function at birth in Cooley’s Anemia kids, and that helps stimulate the production of healthy hemoglobin.
A Moving Change
July 10, 1994
Unhappy with the medical profession’s handling of Rocco’s case and slow progress in researching and treating the rare disease, Girondi did his own extensive research.
The 25 Most Eligible Bachelors in America
July 1, 1988
Just when you thought all the good ones were taken, we’ve found the country’s most desirable unmated men…
Fonzie Gets Rich
April 1, 1987
He used to hate money and power. Now Patrick Finley Girondi has athe money, but he still hates the power…
'Poor man' Finley's story is a rich one
July 7, 1986
You can’t judge a book by its cover. So discovered Chicago literary agent Samuel Freitfeld when he agreed to represent Patrick Finley after reading…
County clerk candidate generous as he is ornery
January 23, 1986
A Southwest Side businessman whose decision to run for Cook County clerk threw a wild card into the race has donated thousands of dollars to community groups
'Diamond' details life on South Side
July 20, 1986
A self-styled “bad boy” and lifelong resident of Chicago’s South Side. Patrick M. Finley has added a novel, “Diamond in the Rough,” to his resume.
Finley Holds Annual Pumpkin Jamboree
October 25, 1986
Pat Finley and the Finley Youth Foundation will hold their “Great Pumpkin Give-A-Way” on Saturday, October 25, 1986…
Trading Faces: A look at the many sides of Pat Finley
December 14, 1986
Pat Finley keeps his Rolls-Royce in the garage. He doesn’t like to drive it because it makes him feel rich…
Party for kids is Santa's "Thank you"
December 21, 1983
Patrick M. Finley, a 26-year-old reincarnation of a Horatio Alger character who strongly identifies with the concepts of “family” and “ethnicity,” stood quietly in a nearby corner exhausted.
New Valentine board member
1980
Patrick Finley was re cenly nominated to the Valentine Chicago Boys
Club Board of Managers. Pat is the youngest individual ever to be nominated
to the Valentine Board of Manager